natgillin/translations-raw huggingface dataset:
How does Clopidogrel DURA work? 
Kako zdravilo Clopidogrel DURA deluje?
1 bottle 
1 stekleničke
40 mg/ml Oral solution bottle (glass) 
40 mg/ml peroralna raztopina Peroralna uporaba stekleničke (iz stekla)
The reasons being the following: 
Razlogi so bili naslednji:
BACKGROUND INFORMATION (2) 
OSNOVNE INFORMACIJE (2)
The Reference Member State was France and the Concerned Member States were Belgium, the Czech Republic, Germany, Italy, Spain and the United Kingdom. 
Referenčna država članica je bila Francija, zadevne države članice pa Belgija, Češka, Nemčija, Italija, Španija in Združeno kraljestvo.
The withdrawal period for milk was 2.5 days. 
Karenca za mleko je bila 2,5 dneva.
The final opinion was converted into a Decision by the European Commission on 5 September 2008. 
Končno mnenje je bilo spremenjeno v sklep Evropske komisije z dnem 5. septembra 2008.
Belgium referred the issue to the EMEA on 28 July 2005. 
Belgija je zadevo zato napotila na agencijo EMEA dne 28. julija 2005.
The product was accepted by the Czech Republic, Italy and Spain. 
Zdravilo so potrdile Češka, Italija in Španija.
During the written procedure a request was received from France for a scientific assessment of new studies made available by the Marketing Authorisation Holder. 
Med pisnim postopkom je Francija posredovala prošnjo za znanstveno oceno novih študij, ki jih je dal na razpolago imetnik dovoljenja za promet.
The arbitration procedure started on 8 September 2005 with the adoption of a list of questions. 
Arbitražni postopek se je pričel 8. septembra 2005 s sprejemom seznama vprašanj.
The reasons for the suspension were the same as those identified in the May 2006 CVMP meeting. 
Razlogi za začasni preklic so bili enaki kot na zasedanju CVMP maja 2006.
The procedure for evaluation of the new data started on 15 April 2008. 
Postopek ocenjevanja novih podatkov se je pričel 15. aprila 2008.
On 25 October 2006 the European Commission forwarded a draft decision to the Standing Committee on Veterinary Medicinal Products for adoption by written procedure. 
Dne 25. oktobra 2006 je Evropska komisija posredovala osnutek svojega sklepa Stalnemu odboru za zdravila za uporabo v veterinarski medicini v sprejem po pisnem postopku.
The product is used in the treatment of respiratory infections caused by Pasteurella multocida and Mannheimia haemolytica in cattle and for the treatment of respiratory infections due to Pasteurella multocida in pigs. 
Zdravilo se uporablja pri zdravljenju okužb dihal, ki jih povzročata Pasteurella multocida in Mannheimia haemolytica pri govedu, ter za zdravljenje okužb dihal, ki jih povzroča Pasteurella multocida pri prašičih.
The rapporteur was Mr. J. Schefferlie and the co-rapporteur was Prof. R. Kroker. 
Poročevalec je bil dr. J. Schefferlie, soporočevalec pa prof. R. Kroker.
• the currently authorised withdrawal periods are inadequate to ensure that foodstuffs obtained from treated animals do not contain residues which might constitute a health hazard to the consumer. 
• trenutno odobrene karence ne zagotavljajo, da živila, proizvedena s predelavo zdravljenih živali, ne vsebujejo za potrošnikovo zdravje potencialno nevarnih ostankov.
Concerns were raised by Belgium, Germany and the United Kingdom regarding the inadequacy of the withdrawal periods and the applications were withdrawn from these countries. 
Belgija, Nemčija in Združeno kraljestvo pa sta izrazili pomisleke glede ustreznosti karenc in vloge so bile v obeh državah umaknjene.
The rapporteur was Mrs. R. Kearsley and the co-rapporteur was Prof. C. Friis. 
Poročevalka je bila ga. dr. R. Kearsley, soporočevalec pa prof. C. Friis.
A mutual recognition procedure was started on 28 April 2005. 
Postopek medsebojnega priznavanja se je pričel 28. aprila 2005.
The detailed grounds for the request were submitted to the EMEA on 18 July 2006 and the evaluation procedure for the re-examination started on 19 July 2006. 
Podrobna podlaga za to prošnjo je bila agenciji EMEA predložena dne 18. julija 2006, 19. julija 2006 pa se je pričel postopek vrednotenja v okviru ponovne presoje.
Therefore, the Committee adopted by consensus an opinion recommending the lifting of the suspension of the marketing authorisations for the above-mentioned product. 
Odbor je zato soglasno sprejel mnenje, s katerim priporoča umik začasnega preklica dovoljenj za promet za zgoraj navedeni zdravili.
• the currently established withdrawal periods for cattle and pigs are inadequate to ensure that residues do not exceed the MRLs; 
• trenutno določene karence za govedo in prašiče ne zagotavljajo, da ostanki ne bodo presegli mejnih vrednosti ostankov (MRL);
During its June 2006 meeting, the CVMP appointed Dr. R. Breathnach as rapporteur for the assessment of the grounds for the request for re-examination of the opinion. 
Med svojim zasedanjem junija 2006 je CVMP določil dr. R. Breathnacha za poročevalca pri ocenjevanju oz. za ponovno presojo mnenja.
The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the SPC in Annex III. 
Seznam zadevnih imen proizvodov je naveden v Dodatku I. Znanstveni zaključki so podani v Dodatku II, povzetek glavnih značilnosti zdravila pa v Dodatku III.
On 14 November 2006 the European Commission suspended the written procedure and on 16 November 2006, requested the CVMP to consider the new residue studies in the assessment of the referral and to revise as appropriate the opinion of 13 September 2006. 
Dne 14. novembra 2006 je Evropska komisija prekinila pisni postopek ter 16. novembra 2006 zaprosila CVMP, naj v svoji oceni razlogov za napotitev upošteva tudi nove študije ostankov in ustrezno dopolni svoje mnenje z dne 13. septembra 2006.
The scope of the referral was to agree whether the proposed withdrawal periods of 58 days for cattle and 35 days for pigs were adequately established. 
Namen napotitve je bila uskladitev mnenj glede tega, ali sta bili predlagani karenci 58 dni za govedo in 35 dni za prašiče pravilno določeni.
Furthermore, the Committee recommends varying the marketing authorisations of the veterinary medicinal products referred to in Annex I in accordance with the Summary of Product Characteristics (SPC) as set out in Annex III. 
Odbor poleg tega priporoča spremembo dovoljenj za promet za zdravila za uporabo v veterinarski medicini, navedena v Dodatku I, v skladu s povzetkom glavnih značilnosti zdravila, navedenem v Dodatku III.
The Marketing Authorisation Holder submitted further new residue studies to the CVMP on 14 April 2008. 
Imetnik dovoljenja za promet je odboru CVMP dne 14. aprila 2008 predložil nove študije ostankov.
On 1 June 2006, the MAH notified the EMEA of its intention to request the reexamination of the CVMP opinion in accordance with Article 36(4)2. 
Dne 1. junija 2006 je imetnik dovoljenja za promet obvestil agencijo EMEA, da namerava ponovno zaprositi CVMP za preučitev karence v skladu s členom 36(4)2.
FOLLOW-UP OPINION FOLLOWING AN ARTICLE 351 REFERRAL FOR Suramox 15 % LA and its associated name Stabox 15 % LA International Non-Proprietary Name (INN): Amoxicillin 
DODATNO MNENJE V ZVEZI Z NAPOTITVIJO V SKLADU S ČLENOM 351 ZA Suramox 15 % LA in z njim povezano ime Stabox 15 % LA Mednarodno nelastniško ime (INN): amoksicilin
• it was not possible to establish a withdrawal period for cattle and pigs based on the data available; 
• na podlagi predloženih podatkov ni bilo mogoče določiti karence za govedo in prašiče;
A Marketing Authorisation for Suramox 15% LA was previously granted to Virbac S.A. in France on 6 July 2004 based on an abridged application citing Duphamox LA as reference medicinal product. 
Dovoljenje za promet za zdravilo Suramox 15 % LA je bilo prvotno podeljeno podjetju Virbac S.A. iz Francije dne 6. julija 2004, in sicer na podlagi skrajšane vloge, v kateri je bilo zdravilo Duphamox LA navedeno kot referenčno zdravilo.
The Marketing Authorisation Holder submitted the new residue studies to the CVMP on 9 January 2007 and provided oral explanations to the Committee on 13 March 2007. 
Imetnik dovoljenja za promet je nove študije ostankov posredoval CVMP dne 9. januarja 2007 ter 13. marca 2007 Odboru podal tudi ustna pojasnila.
In both species the product is administered intramuscularly at a dose of 15 mg amoxicillin/kg bw (equivalent to 1 ml of Suramox 15% LA / 10 kg bw) twice with a 48 hour interval between doses. 
Pri obeh živalskih vrstah se zdravilo daje dvakrat v 48-urnem razmaku med obema injiciranjima, in sicer intramuskularno v odmerku 15 mg amoksicilina/1 kg telesne mase (kar je enakovredno 1 ml zdravila Suramox 15 % LA/10 kg telesne mase).
The Marketing Authorisation Holder (MAH) subsequently provided written explanations to the Committee on 16 January 2006. 
Imetnik dovoljenja za promet je dne 16. januarja 2006 Odboru predložil pisna pojasnila.
The withdrawal periods established for Suramox 15% LA were 58 days in cattle for meat and offal and 35 days in pigs for meat and offal. 
Karenca, določena za zdravilo Suramox 15 % LA, je bila 58 dni pri govedu za meso in drobovino ter 35 dni pri prašičih za meso in drobovino.
On 13 June 2007 the European Commission adopted a Commission Decision suspending the national marketing authorisations for Suramox 15% LA and Stabox 15% LA, but providing an opportunity for the decision to be reviewed further to a new opinion formulated by the CVMP on the basis of the assessment of new residue depletion studies. 
Dne 13. junija 2007 je Evropska komisija sprejela sklep, s katerim izreka začasni preklic nacionalnih dovoljenj za promet za zdravili Suramox 15 % LA in Stabox 15 % LA, ki pa hkrati dopušča možnost ponovne presoje tega sklepa v primeru, da bo CVMP na podlagi ocene novih študij o izločanju ostankov sprejel novo mnenje.
On 14 March 2007 the CVMP, having considered the new residue studies, concluded that it was not possible to set a withdrawal period for Suramox 15% LA and Stabox 15% LA, for either cattle or pig meat and offal and therefore recommended by consensus the suspension of the above marketing authorisations for the above-mentioned products. 
Dne 14. marca 2007 je CVMP ob upoštevanju novih študij ostankov zaključil, da za zdravili Suramox 15 % LA in Stabox 15 % LA ni mogoče določiti karence ne za goveje meso in drobovino niti za meso in drobovino prašičev, zaradi česar je soglasno sprejel priporočilo, da se zgoraj omenjena dovoljenja za promet za zadevna zdravila začasno prekličejo.
During its June 2008 meeting the CVMP considered the new residue studies submitted with regard to Suramox 15% LA and concluded that withdrawal periods can now be set for both cattle and pigs for Suramox 15% LA and Stabox 15% LA. 
CVMP je na svojem zasedanju v juniju 2008 preučil nove študije ostankov, predložene za zdravilo Suramox 15% LA, in zaključil, da je sedaj za zdravili Suramox 15% LA in Stabox 15 % LA možno določiti karenco tako za govedo kot tudi za prašiče.
On 13 September 2006 the CVMP considered the detailed grounds for the re-examination of the opinion and confirmed its previous opinion concluding that the marketing authorisations for Suramox 15% LA should be suspended. 
Dne 13. septembra 2006 je CVMP obravnaval dostavljeno dokumentacijo in potrdil svoje prvotno mnenje, s katerim priporoča začasni preklic dovoljenja za promet za zdravilo Suramox 15 % LA.
Suramox 15% LA is an injectable suspension containing amoxicillin, which is a beta-lactam antibiotic belonging to the penicillin group. 
Zdravilo Suramox 15 % LA je suspenzija za injiciranje, ki vsebuje amoksicilin, t.j.
During its May 2006 meeting, the CVMP, in light of the overall data submitted and the scientific discussion within the Committee, adopted by consensus an opinion recommending the suspension of the marketing authorisations for Suramox 15% LA and the Stabox 15% LA, for cattle and pigs. 
Med svojim zasedanjem maja 2006 je CVMP na podlagi vseh posredovanih podatkov in znanstvene razprave soglasno sprejel mnenje in z njim priporočil začasni preklic dovoljenja za promet z zdraviloma Suramox 15 % LA in Stabox 15 % LA, namenjenima za zdravljenje goveda in prašičev.
There were three groups in this study. 
V tej raziskavi so bile tri skupine.
There is no experience in children. 
Izkušenj pri otrocih ni.
(95% confidence interval) 
(95% interval zaupanja)
(Percent of Patients) 
(odstotek bolnikov)
Infections may progress more rapidly and be more severe. 
Okužbe lahko napredujejo hitreje in so hujše.
Patient's Name: _____________________ Doctor's Name: _____________________ Doctor's Phone: _____________________ 
Zdravnikovo ime: ____________________ Zdravnikov telefon: ____________________
Other opportunistic infections: 
Druge oportunistične okužbe:
If this happens, do not use the syringe or vial. 
Če se to zgodi, brizge ali viale ne uporabite.
Some patients were treated for up to 60 months duration. 
Nekatere bolnike so zdravili do 60 mesecev.
In Study III, these improvements were maintained throughout 52 weeks. 
V raziskavi III so se ta izboljšanja ohranila 52 tednov.
Quality of Life 
Kvaliteta življenja
This includes tuberculosis. 
To velja tudi za tuberkulozo.
Available data suggest that Trudexa does not worsen or cause strictures. 
Razpoložljivi podatki kažejo, da Trudexa ne poslabša in ne povzroči striktur.
The injection is complete when the yellow indicator stops moving. 
Injiciranje je končano, ko se rumeni kazalnik neha premikati.
It should be noted that in the majority of those reports, tuberculosis was extra-pulmonary, i.e. disseminated. 
Opozoriti je treba, da je bila v večini teh primerov tuberkuloza zunajpljučna, tj. diseminirana.
An updated risk management plan should be provided as per the CHMP guideline on the risk management systems for medicinal products for human use. 
Predložen bo posodobljen načrt upravljanja tveganja (“Risk Management Plan”) v skladu z navodili odbora CHMP “Guideline on the risk management systems for medicinal products for human use”.
Study III also had a primary endpoint of changes in quality of life. 
Študija III je imela kot primarno končno točko tudi spremembe v kakovosti življenja.
Tuberculosis: 
Tuberkuloza:
• protein in urine. 
• beljakovine v urinu.
This may cause severe allergic reactions in patients sensitive to latex. 
To lahko povzroči hude alergijske reakcije pri bolnikih, občutljivih za lateks.
Because the elimination of adalimumab may take up to five months, monitoring should be continued throughout this period. 
Ker lahko eliminacija adalimumaba traja do pet mesecev, je treba bolnike ves ta čas nadzirati.
Significant response was first observed at Week 2 and maintained through 24 weeks (Table 8). 
Značilen odziv so najprej opazili po 2 tednih in se je ohranil do 24. tedna (tabela 8).
What should I do before I give myself a subcutaneous injection of Trudexa? 
Kaj moram narediti, preden si dam podkožno injekcijo Trudexe?
Serious infections: 
Resne okužbe:
Table 1 Undesirable Effects in Clinical Studies 
Tabela 1 Neželeni učinki v kliničnih študijah
For all of the above indications, available data suggest that the clinical response is usually achieved within 12 weeks of treatment. 
Dosegljivi podatki za vse navedene indikacije kažejo, da se klinični odziv ponavadi pojavi v 12 tednih zdravljenja.
Puerto Rico 00617 
Puerto Rico 00617 ZDA
The marketing authorisation holder should submit 6 monthly periodic safety update reports. 
Imetnik dovoljenja za promet z zdravilom mora predložiti periodično poročilo o varnosti zdravila vsakih 6 mesecev.
The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the pharmacovigilance plan. 
Imetnik dovoljenja za promet se zavezuje, da bo izvedel študije in dodatne farmakovigilančne aktivnosti, ki so opredeljene v farmakovigilančnem načrtu.
• You should be screened for tuberculosis. 
• Opraviti morate presejalne preiskave za tuberkulozo.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 1 September 2003 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET 1. september 2003
Since Trudexa is given subcutaneously, food and drink should not affect Trudexa. 
Ker se Trudexa uporablja subkutano, hrana in pijača naj ne bi vplivali na Trudexo.
Do NOT remove the grey stopper or aluminium ring around the top of the vial. 
NE ODSTRANITE sivega zamaška ali aluminijastega obročka na vrhu viale.
Therefore, the combination of adalimumab and anakinra is not recommended. 
Zato kombinacija adalimumaba in anakinre ni priporočena.
After cleaning, do not touch the stopper with your hands. 
Po očiščenju se zamaška ne dotikajte več z rokami.
Trudexa in combination with methotrexate, is indicated for: 
Trudexa je v kombinaciji z metotreksatom indicirana za:
Trudexa increases the risk of getting infections. 
Trudexa zvečuje tveganje za okužbe.
• sensation of heart beating rapidly, high blood pressure; 
• občutek hitrega bitja srca, visok krvni pritisk;
• allergic reactions; 
• alergijske reakcije;
Monoclonal antibodies are proteins that recognise and bind to other unique proteins. 
Monoklonska protitelesa so beljakovine, ki prepoznajo druge specifične beljakovine in se nanje vežejo.
Patients who have a known sensitivity to latex should be advised to avoid touching the inner shield. 
Bolnikom z znano občutljivostjo za lateks je treba naročiti, da se ne smejo dotikati notranjega ščitnika.
There are two caps - one is grey and labelled ‘1' and the other is plum and labelled ‘2'. 
Nameščena ima dva pokrovčka - eden je siv in označen z '1', drugi pa temnomoder in označen z '2'.
Tell your doctor immediately if you notice any of the following: 
Svojemu zdravniku takoj povejte, če opazite kaj od naslednjega:
Using Trudexa with food and drink 
Uporaba zdravila Trudexa skupaj s hrano in pijačo
• Show this card to any doctor involved in your treatment. 
• To izkaznico pokažite vsakemu zdravniku, ki vas zdravi.
Concomitant stable doses of aminosalicylates, corticosteroids, and/or immunomodulatory agents were permitted and 79% of patients continued to receive at least one of these medications. 
Dovoljena je bila sočasna uporaba stabilnih odmerkov aminosalicilatov, kortikosteroidov in/ali imunomodulacijskih zdravil; 79% bolnikov je še naprej prejemalo vsaj eno od takšnih zdravil.
If you use more Trudexa than you should: 
Če ste uporabili večji odmerek Trudexe, kot bi smeli
• In some patients the body may fail to produce enough of the blood cells that help your body fight infections or help you to stop bleeding. 
• Pri nekaterih bolnikih telo ne ustvari dovolj krvnih celic, ki pomagajo pri premagovanju okužbe ali ustavitvi krvavitve.
In addition, ACR response rates were maintained in the majority of patients followed in the open-label extension phase to week 104. 
Poleg tega se je delež odziva po ACR ohranil pri večini bolnikov, ki so jih med odprto nadaljevalno fazo spremljali do 104. tedna.
Trudexa was studied in 5293 patients in controlled and open label trials for up to 60 months. 
Trudexo so raziskali pri 5293 bolnikih v kontroliranih in odprtih preskušanjih, ki so trajala do 60 mesecev.
• Keep this card with you for 5 months after the last Trudexa dose, since side effects may occur a long time after your last dose of Trudexa. 
• To izkaznico imejte pri sebi še 5 mesecev po zadnjem odmerku Trudexe, kajti neželeni učinki se lahko pojavijo še dolgo časa po zadnjem odmerku tega zdravila.
The effects of Trudexa in pregnant women are not known and so the use of Trudexa in pregnant women is not recommended. 
Vplivi Trudexe pri nosečnicah niso znani, zato uporaba tega zdravila pri nosečih ženskah ni priporočljiva.
Maintenance of clinical remission was evaluated in CHARM. 
Vzdrževanje klinične remisije je ocenjevala študija CHARM.
• anxiety, depression, feeling sleepy and difficulty sleeping; 
• tesnobnost, depresija, zaspanost in težave s spanjem;
Hepatitis B Reactivation 
Reaktivacija hepatitisa B
It is a medicine that decreases the inflammation process of these diseases. 
Je zdravilo, ki ublaži vnetno dogajanje pri teh boleznih.
• If you have a severe infection, including active tuberculosis (see “Take special care with Trudexa”). 
• če imate hudo okužbo, vključno z aktivno tuberkulozo (glejte "Bodite posebno pozorni pri uporabi Trudexe").
In all studies (I-VII), patients with raised ALT were asymptomatic and in most cases elevations were transient and resolved on continued treatment. 
V vseh študijah (I-VII) so bili bolniki, ki so imeli zvišano ALT, asimptomatski; zvišanje je bilo večinoma prehodno in je med nadaljevanjem zdravljenja minilo.
Clinical remission results remained relatively constant irrespective of previous TNF antagonist exposure. 
Rezultati glede klinične remisije so ostali razmeroma stalni, ne glede na prejšnje prejemanje antagonistov TNF.
ACR responses in Study VI were similar with and without concomitant methotrexate therapy. 
Odzivi ACR v študiji VI so bili podobni ob sočasni terapiji z metotreksatom in brez nje.
• tuberculosis and other opportunistic infections (infections that occur when resistance to disease is lowered); 
• tuberkuloza in druge oportunistične okužbe (okužbe, ki se pojavijo, kadar se zmanjša odpornost proti boleznim);
Then take your next dose as you would have on your originally scheduled day, had you not forgotten a dose. 
Nato uporabite naslednji odmerek, kot bi ga uporabili po prvotnem urniku, če ne bi pozabili odmerka.
Improvement in quality of life was measured up to week 156 (36 months) and improvement was maintained through that time. 
Izboljšanje kvalitete življenja se je ocenjevalo do 156. tedna (36. meseca).
• Pull the needle completely out of the vial. 
• Iglo popolnoma potegnite iz viale.
It is important to tell your doctor if you have had or have a serious heart condition (see “Take special care with Trudexa”). 
Pomembno je, da zdravniku poveste, če ste imeli ali imate kakšno resno bolezen srca (glejte "Bodite posebno pozorni pri uporabi Trudexe").
Store in a refrigerator (2°C - 8°C). 
Shranjujte v hladilniku (2 °C - 8 °C) .
Trudexa is injected under the skin (subcutaneous use). 
Trudexa se injicira pod kožo (subkutana uporaba).
Appropriate screening tests, i.e. tuberculin skin test and chest X-ray, should be performed in all patients (local recommendations may apply). 
Pri vseh bolnikih je treba narediti ustrezne presejalne preiskave, tj. tuberkulinski kožni test in rentgensko slikanje prsnih organov (veljajo lahko lokalna priporočila).
The highest dose level evaluated has been multiple intravenous doses of 10 mg/kg. 
Največji ocenjeni odmerek je obsegal večkratno intravensko aplikacijo 10 mg/kg.
Place the white end of the pre-filled pen at a right angle (90 degrees) to the skin, so that you can see the window. 
Namestite beli konec napolnjenega injekcijskega peresnika pravokotno (90 stopinj) na kožo, tako da boste videli okence.
Induction of clinical remission (defined as CDAI < 150) was evaluated in two studies, CLASSIC I and GAIN. 
Indukcijo klinične remisije (opredeljene kot CDAI < 150) so ocenili v dveh študijah, CLASSIC I in GAIN.
Before initiation of therapy with Trudexa, all patients must be evaluated for both active or inactive (latent) tuberculosis infection. 
Pred začetkom zdravljenja s Trudexo je vse bolnike treba pregledati glede aktivne ali neaktivne (latentne) tuberkulozne okužbe.
• Severe rash, hives or other signs of allergic reaction; 
• hud izpuščaj, koprivnico ali druge znake alergijske reakcije;
The average absolute bioavailability of adalimumab estimated from three studies following a single 40 mg subcutaneous dose was 64%. 
Povprečna absolutna biološka uporabnost adalimumaba, ocenjena iz treh raziskav po enem 40 mg odmerku subkutano, je 64%.
• The Trudexa syringe should NEVER be reused. 
• Brizge s Trudexo NIKDAR ne smete ponovno uporabiti.
It is not known whether adalimumab passes into breast milk. 
Ni znano, ali se adalimumab izloča v materinem mleku.
If you forget to give yourself an injection, you should inject the next dose of Trudexa as soon as you remember. 
Če si pozabite dati injekcijo, si morate naslednji odmerek Trudexe injicirati, čim se spomnite.
Trudexa has not been studied in these patient populations. 
Trudexa pri teh populacijah bolnikov še ni bila preskušena.